Skip to main content
Log in

Nebenwirkungen der medikamentösen Tumortherapie

Was Internisten wissen sollten

Side effects of tumor pharmacotherapy

What internists should know

  • CME Weiterbildung · Zertifizierte Fortbildung
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Seit den 1950er Jahren werden Zytostatika in der Tumortherapie eingesetzt. Über Anwendungsbeobachtungen und Dosisfindungsstudien mussten die tolerablen Dosierungen ermittelt werden. Auch heute verursachen viele Chemotherapieprotokolle noch erhebliche, teils lebensbedrohliche Nebenwirkungen. Übelkeit und Erbrechen gehören zu den häufigsten Beschwerden, weiterhin Mukositis, Müdigkeit und Schwäche. Die mögliche Knochenmarktoxizität führt zu erhöhter Infektionsneigung sowie gelegentlich zu Blutungen. Schäden an den Nieren, der Leber, dem Herzen, der Lunge, der Haut oder dem Nervensystem treten medikamentenabhängig auf. Da ein Großteil der Tumortherapien heute ambulant durchgeführt werden kann, kommt dem niedergelassenen Arzt eine wichtige Rolle in der Betreuung seiner Patienten mit den durch Zytostatika induzierten Nebenwirkungen zu.

Abstract

Cytotoxic drugs have been used in the therapy of malignant tumors for the last 70 years. However, side effects of cytotoxic drugs are very common and often dose-limiting. Although many protocols have been optimized, side effects are still frequently life-threatening. Nausea and vomiting are among the most frequently reported side effects, in addition to mucositis and fatigue. Bone marrow toxicity can lead to neutropenic sepsis, thrombocytopenic bleeding, or anemia with the respective sequelae. In addition to these unspecific side effects, organ toxicity is class or drug specific and may involve the kidney, liver, heart, lung, skin, or central nervous system. As most protocols can be administered on an outpatient basis, knowledge of these side effects is important for the general internist.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Benson AB, Ajani JA, Catalano RB et al (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhoa. J Clin Oncol 22:2918

    Article  PubMed  CAS  Google Scholar 

  2. Blajchman MA (2002) Incidence and significance of the bacterial contamination of blood components. Dev Biol (Basel) 108:59–67

    Google Scholar 

  3. Block KI, Koch AC, Mead MN et al (2008) Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials. Int J Cancer 123:1227–1239

    Article  PubMed  CAS  Google Scholar 

  4. Carson JL, Duff A et al (1996) Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 348:1055–1060

    Article  PubMed  CAS  Google Scholar 

  5. Corwin HL, Carson JL (2007) Blood transfusion – when is more really less? N Engl J Med 356:1667–1669

    Article  PubMed  CAS  Google Scholar 

  6. Czaykowski PM, Moore MJ, Tannock IF (1998) High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 160:2021–2024

    Article  PubMed  CAS  Google Scholar 

  7. Hölig K, Kramer M, Kroschinsky F et al (2009) Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 yrs of single-center experience in 3928 donors. Blood 114:3757–3763

    Article  PubMed  Google Scholar 

  8. Holmes FA, O’Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727–731

    Article  PubMed  CAS  Google Scholar 

  9. Hughes WT, Armstrong D, Bodey GP et al (2002) Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730

    Article  PubMed  Google Scholar 

  10. Kris MG, Hesketh PJ, Sommerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932

    Article  PubMed  CAS  Google Scholar 

  11. Likun Z, Xiang J, Yi B et al (2011) A systematic review and meta-analysis of intravenous palonsetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist 16:207–216

    Article  PubMed  Google Scholar 

  12. Lo N, Cullen M (2006) Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider. Hematol Oncol 24:120–125

    Article  PubMed  Google Scholar 

  13. Pinto C, Barone CA, Girolomoni G et al (2011) Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 16:228–238

    Article  PubMed  Google Scholar 

  14. Roila F, Herrsted JAapro M et al; ESMO/MASCC Guidelines Working Group (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21 (Suppl 5):v232–v243

    Article  PubMed  Google Scholar 

  15. Schlippe M von, Fowler CJ, Harland SJ (2001) Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. Br J Cancer 85:823–826

    Article  Google Scholar 

  16. Schmidt AH, Mengling T, Pingel J et al (2010) Follow-up of 12,559 unrelated donors of peripheral blood stem cells or bone marrow. ASH Annual Meeting Abstracts. Blood 116: Abstr 365

    Article  Google Scholar 

  17. Siegal T, Haim N (1990) Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 66:1117–1123

    Article  PubMed  CAS  Google Scholar 

  18. Wong M, Choo SP, Tan EH (2009) Travel warning with capecitabine. Ann Oncol 20:1281

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to E. Wollmer or A. Neubauer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wollmer, E., Neubauer, A. Nebenwirkungen der medikamentösen Tumortherapie. Internist 52, 1429–1446 (2011). https://doi.org/10.1007/s00108-011-2930-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-011-2930-4

Schlüsselwörter

Keywords

Navigation